<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121211</url>
  </required_header>
  <id_info>
    <org_study_id>2009P-001845/1</org_study_id>
    <secondary_id>5R01MH083657-05A2</secondary_id>
    <nct_id>NCT01121211</nct_id>
  </id_info>
  <brief_title>Hormonal Factors in the Treatment of Anorexia Nervosa</brief_title>
  <official_title>Hormonal Factors in the Treatment of Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are investigating whether a hormone that is naturally produced by the human
      body, called testosterone, can help improve weight, disordered eating, depression, and
      anxiety. The investigators hypothesize that testosterone will be a novel and effective
      endocrine-targeted therapy for patients with anorexia nervosa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Weight in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Depression Symptom Severity</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>Hamilton Depression Rating Scale (HAM-D) (Higher score = greater depression symptom severity; Score Range 0 - ≥ 23)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Anorexia Nervosa</condition>
  <condition>Eating Disorder</condition>
  <condition>Anxiety</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone x 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo x 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone 300mcg transdermal patch x 24 weeks.</description>
    <arm_group_label>Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo transdermal patch x 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18- 45 years; if participating in the neuroimaging sub study, age 18-40

          -  Meet DSM-IV criteria for AN (restricting or binge/purge type, BMI 15-17.5) OR meet
             criteria for sub-threshold AN, i.e., all DSM-IV criteria except that patients can have
             a BMI of &lt;18.5 kg/m2 with or without amenorrhea.

          -  Free T below the median for healthy women of reproductive age

          -  All participants will be required to have a treatment team in place that consists of
             (at least) a primary care physician and a psychotherapist. Participants will need to
             have had regular contact with a primary care physician and be in an individual
             psychotherapy program. Participants will agree to continue with this treatment team
             and therapy throughout the active course of the study. If participants are taking
             psychotropic medications, the dose must be stable for 3 months before study entry

        Exclusion Criteria:

          -  Pregnant women or women of child bearing potential who are not using medically
             accepted means of contraception (to include oral contraceptive, patch or implant,
             condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with
             vasectomy).

          -  Unstable medical illness, including cardiovascular, hepatic, renal, respiratory,
             endocrine, neurologic

          -  Serious suicide risk, substance use disorder active within last 6 months, bipolar I
             disorder, severe current depressive symptoms (indexed by HAM-D score &gt;20 [excluding 2
             eating/weight loss items related to the symptoms of AN]), or psychotic disorder

          -  New psychotropic drug regimen, specifically a significant dose change or change in
             drug class, within the last 6 weeks. A study psychiatrist will assess whether PRN
             medications and dose changes are clinically significant enough to defer enrollment of
             specific potential study subjects.

          -  Untreated hypothyroidism

          -  If receiving estrogen therapy, including oral contraceptives or transdermal estrogen
             therapy, significant change in dose in the prior 3 months

          -  Use of androgens or androgen precursors, including T, DHEA and methyl T, within 3
             months

          -  Any investigational psychotropic drug within the last 3 months

          -  In the judgment of the study clinician, unlikely to be able to participate safely
             throughout the study period

          -  Alanine aminotransferase (ALT) &gt; 2x upper limit of normal

          -  Creatinine &gt;1.5x upper limit

          -  Serum potassium &lt; lower limit of normal

          -  If participating in the sub study, unable to tolerate 1 hour in MRI; contraindication
             to MRI (such as implanted pacemaker, cerebral aneurysm clips, extensive orthopedic
             hardware instrumentation); gastrointestinal tract surgery (including gastrectomy,
             gastric bypass surgery, and small or large bowel resection); history of psychosis by
             SCID
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Klibanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen K Miller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erinne Meenaghan, NP</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>January 25, 2017</results_first_submitted>
  <results_first_submitted_qc>March 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2017</results_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Anne Klibanski, MD</investigator_full_name>
    <investigator_title>Chief, Neuroendocrine Unit</investigator_title>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Hormones</keyword>
  <keyword>Mental Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Testosterone</title>
          <description>Testosterone x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo x 24 weeks
Placebo: Placebo transdermal patch x 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone</title>
          <description>Testosterone x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.
Placebo: Placebo transdermal patch x 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.
Placebo: Placebo transdermal patch x 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="7"/>
                    <measurement group_id="B2" value="27" spread="7"/>
                    <measurement group_id="B3" value="27" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight</title>
        <description>Weight in kilograms</description>
        <time_frame>Baseline, 24 Weeks</time_frame>
        <population>All subjects who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone</title>
            <description>Testosterone x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.
Placebo: Placebo transdermal patch x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.
Placebo: Placebo transdermal patch x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <description>Weight in kilograms</description>
          <population>All subjects who received at least one dose of study medication</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.7"/>
                    <measurement group_id="O2" value="1.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Depression Symptom Severity</title>
        <description>Hamilton Depression Rating Scale (HAM-D) (Higher score = greater depression symptom severity; Score Range 0 - ≥ 23)</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>All subjects who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone</title>
            <description>Testosterone x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.
Placebo: Placebo transdermal patch x 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.
Placebo: Placebo transdermal patch x 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Depression Symptom Severity</title>
          <description>Hamilton Depression Rating Scale (HAM-D) (Higher score = greater depression symptom severity; Score Range 0 - ≥ 23)</description>
          <population>All subjects who received at least one dose of study medication</population>
          <units>HAM-D score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="5"/>
                    <measurement group_id="O2" value="-3" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Testosterone</title>
          <description>Testosterone x 24 weeks
Testosterone: Testosterone 300mcg transdermal patch x 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo x 24 weeks
Placebo: Placebo transdermal patch x 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to exacerbation of GI disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to anorexia nervosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hospitalization due to depression exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne or Increase in acne</sub_title>
                <description>Adverse event data collected at each study visit.</description>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Patch site irritation</sub_title>
                <description>Adverse event data collected at each study visit.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oily skin or Increase in oily skin</sub_title>
                <description>Adverse event data collected at each study visit.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hirsutism or Increased hair growth</sub_title>
                <description>Adverse event data collected at each study visit.</description>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Depilation</sub_title>
                <description>Adverse event data collected at each study visit.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anne Klibanski</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177263870</phone>
      <email>aklibanski@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

